tirzepatide and multiple sclerosis The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Sclerosis: A Narrative Review Mounjaro and Multiple Sclerosis: Safety

This hormone also slows down the rate at which the gastrointestinal system works, helping you to feel full and decreasing hunger

Most people regain 35-50% of lost weight by six months and approach their baseline weight by 12 months if no lifestyle changes maintain the loss

Conclusions/interpretation Our findings do not support an increased risk of SIS when taking GLP-1RA in individuals with type 2 diabetes and obesity

10.1016/j.jsgi.2003.09.004 15 BogusiewiczM.Stryjecka-ZimmerM.PostawskiK.JakimiukA

Other Possible Effects : Oral versions may cause mild digestive issues

MASLD: a systemic metabolic disorder with cardiovascular and malignant complications